Michelle Patricia Pernice - 06 Nov 2026 Form 3 Insider Report for InMed Pharmaceuticals Inc. (MTRI)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
3
Accepted by SEC
12 Nov 2026, 16:01:07 UTC
Prior SEC filing
10 Sep 2026
Next SEC filing
12 Nov 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jerad G. Seurer, as attorney-in-fact for Michelle Pernice
Filing notes and source

Key filing fact

Michelle Patricia Pernice filed Form 3 for InMed Pharmaceuticals Inc. (MTRI) on 12 Nov 2026.

Key facts

  • This page summarizes Michelle Patricia Pernice's Form 3 filing for InMed Pharmaceuticals Inc. (MTRI).
  • 0 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 12 Nov 2026, 16:01.

Change

  • Previous filing in this sequence was filed on 10 Sep 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002126413 Primary reporting owner

Pernice Michelle Patricia

Relationship
Director
Address
C/O MENTARI THERAPEUTICS, INC., 221 CRESCENT ST., BUILDING 23, SUITE 105, WALTHAM
Signature
/s/ Jerad G. Seurer, as attorney-in-fact for Michelle Pernice
Signature date
12 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MTRI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
27,868
Date
06 Nov 2026
Ownership
Direct
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Effective as of November 6, 2026 (the "Effective Time"), (i) Indigo Merger Sub Corp., a wholly owned subsidiary of Mentari Therapeutics, Inc. (formerly known as InMed Pharmaceuticals Inc.), a Nevada corporation (the "Issuer"), merged with and into Mentari Therapeutics, Inc., a Delaware corporation ("Pre-Merger Mentari"), with Pre-Merger Mentari continuing as a wholly owned subsidiary of the Issuer and the surviving corporation of the merger (the "First Merger"), and (ii) immediately thereafter, Pre-Merger Mentari merged with and into Indigo Merger Sub II, LLC, a second wholly owned subsidiary of the Issuer ("Second Merger Sub"), with Second Merger Sub being the surviving entity of the merger under the name Mentari Therapeutics Operating Company LLC (the "Second Merger" and, together with the First Merger, the "Merger").

Footnote F2

Represents shares of the Issuer's common stock received by the Reporting Person in the Merger in exchange for the shares of Pre-Merger Mentari's common stock held by the Reporting Person prior to the Merger. Each share of Pre-Merger Mentari's restricted common stock held at the Effective Time was exchanged for 0.20065 restricted shares of the Issuer's common stock. Of these shares of common stock, 19,740 remain subject to forfeiture restrictions and vest in equal monthly installments through August 13, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

SEC remarks

Exhibit 24 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .